We interviewed Dr. Fabian Buller, Director of New Ventures at Johnson & Johnson Innovation, and member of our selection committee, on his view of the European startup landscape and what he expects from BaseLaunch candidates.
What is your view about the Swiss and European startup healthcare ecosystem?
I believe the Swiss and European life science ecosystem offers excellent conditions for entrepreneurs and startups to foster their innovation. Innovation can take place anywhere in the world, but the highly-networked environment in Europe can help to bring forward novel ideas: Academics, startups and the industry are typically very open to new collaborations and to new ways on how two (or more) parties can collaborate together – that’s very good. Of course, we want to see even more ideas being tested and translated, and I hope our engagement with BaseLaunch can facilitate some of this within the greater Basel region.
Why do you engage with BaseLaunch?
BaseLaunch offers young startups lab space, non-dilutive funding and a close relationship to the industry. That should be a very attractive package for entrepreneurs. At J&J innovation, we are very keen to facilitate startup growth and to work closely together with entrepreneurs – that is why we are excited about our partnership with BaseLaunch.
What do you look for in potential projects?
Transformative healthcare innovation and individuals who challenge the status quo.
About Dr. Fabian Buller
Fabian is Director of New Ventures at Johnson & Johnson Innovation. Fabian is based in Zurich, Switzerland, and affiliated with Covagen AG, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Before joining the Johnson & Johnson family, Fabian was Director of Business Development at Covagen, a company acquired by Janssen in August 2014. In this role, he helped grow a successful biotech company and was instrumental in entering a strategic research & licensing partnership and, ultimately, in the sale of the company. Fabian holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.